We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+5.24%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$463B
AUM Growth
+$17.5B
Cap. Flow
-$1.61B
Cap. Flow %
-0.35%
Top 10 Hldgs %
12.49%
Holding
2,596
New
97
Increased
1,091
Reduced
793
Closed
67

Sector Composition

Rank Sector Weight
1 Healthcare 16.64%
2 Consumer Discretionary 13.46%
3 Financials 12.79%
4 Industrials 12.13%
5 Technology 9.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SUSQ
1901
DELISTED
SUSQUEHANNA BANCSHARES INC
SUSQ
$546K ﹤0.01%
51,718
+14,300
+38% +$149K
SAFT icon
1902
Safety Insurance
SAFT
$1.52B
$545K ﹤0.01%
10,615
-1,200
-10% -$63.1K
HR icon
1903
Healthcare Realty
HR
$6.58B
$544K ﹤0.01%
22,600
+7,850
+53% +$187K
FURX
1904
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$543K ﹤0.01%
5,118
DY icon
1905
Dycom Industries
DY
$12.3B
$541K ﹤0.01%
17,263
TCF
1906
DELISTED
TCF Financial Corporation Common Stock
TCF
$541K ﹤0.01%
19,261
+2,500
+15% +$73.2K
DWRE
1907
DELISTED
DEMANDWARE INC COM STK (DE)
DWRE
$541K ﹤0.01%
7,800
+1,500
+24% +$86K
PAG icon
1908
Penske Automotive Group
PAG
$14.4B
$540K ﹤0.01%
10,916
UBSI icon
1909
United Bankshares
UBSI
$6.68B
$540K ﹤0.01%
16,700
-300
-2% -$9.13K
JBLU icon
1910
JetBlue
JBLU
$2.19B
$537K ﹤0.01%
49,500
+21,900
+79% +$202K
OMCL icon
1911
Omnicell
OMCL
$1.72B
$537K ﹤0.01%
18,720
CY
1912
DELISTED
Cypress Semiconductor
CY
$537K ﹤0.01%
49,218
+1,323
+3% +$13.4K
FFBC icon
1913
First Financial Bancorp
FFBC
$3.6B
$536K ﹤0.01%
31,142
BOBE
1914
DELISTED
Bob Evans Farms, Inc.
BOBE
$536K ﹤0.01%
10,700
MGLN
1915
DELISTED
Magellan Health Services, Inc.
MGLN
$535K ﹤0.01%
8,600
+1,200
+16% +$70.5K
SMP icon
1916
Standard Motor Products
SMP
$870M
$534K ﹤0.01%
11,950
PES
1917
DELISTED
Pioneer Energy Services Corp.
PES
$533K ﹤0.01%
30,400
B
1918
DELISTED
Barnes Group Inc.
B
$532K ﹤0.01%
13,800
SD
1919
DELISTED
SANDRIDGE ENERGY, INC.
SD
$532K ﹤0.01%
74,359
+16,300
+28% +$110K
TEF
1920
DELISTED
Telefonica
TEF
$531K ﹤0.01%
42,168
MLI icon
1921
Mueller Industries
MLI
$14.7B
$529K ﹤0.01%
72,000
RMBS icon
1922
Rambus
RMBS
$10.8B
$528K ﹤0.01%
36,900
GCO icon
1923
Genesco
GCO
$394M
$526K ﹤0.01%
6,400
NEOG icon
1924
Neogen
NEOG
$2.59B
$524K ﹤0.01%
34,533
+4,533
+15% +$67.3K
ACCO icon
1925
Acco Brands
ACCO
$399M
$522K ﹤0.01%
81,367
+17,700
+28% +$108K

Similar funds

T. Rowe Price Associates's Q2 2014 Portfolio in Review

As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
  • T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
  • T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
  • T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
  • T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
  • T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
  • T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.

Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.